KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients ...

Andrews JL, Shirley PS, Iverson WO, Sherer AD, Markovits JE, King L, Lyons RM, Kaleko M, Connelly S. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic ...